Sensei Biotherapeutics公司宣布,其候选药物Piktor针对晚期子宫内膜癌的II期临床试验关键性数据,预计将于2026年下半年公布。这一时间表为关注该疗法进展的投资者和医学界提供了明确的时间节点。
Sensei Biotherapeutics公司宣布,其候选药物Piktor针对晚期子宫内膜癌的II期临床试验关键性数据,预计将于2026年下半年公布。这一时间表为关注该疗法进展的投资者和医学界提供了明确的时间节点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.